{"url_path":"/sec/cik-0001697884/10-k/2026/item-12","section_key":"item-12","section_title":"Item 12 Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matter.**","topic":"sec","document":{"doc_type":"10-K","doc_date":"2026-06-17","source_url":"https://www.sec.gov/Archives/edgar/data/1697884/0001640334-26-001082-index.html","accession_number":"0001640334-26-001082","cik":"0001697884","ticker":null,"issuer_name":"VITASPRING BIOMEDICAL CO. LTD.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1697884/0001640334-26-001082-index.html","primary_entity_key":"0001697884","primary_entity_name":"VITASPRING BIOMEDICAL CO. LTD."},"word_count":430,"has_tables":true,"body_markdown":"**Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matter.**\n\n \n\n**Security ownership of certain beneficial owners**\n\n \n\nThe following table sets forth the beneficial ownership (and the percentages of outstanding shares represented by such beneficial ownership) as of June 17, 2026, of (i) each of our current directors, (ii) the current NEOs named in the “Summary Compensation Table” contained in this Form 10-K, (iii) each person known to us to be the beneficial owner of more than 5% of the outstanding shares of our common stock based upon Schedules 13G or 13D filed with the SEC; and (iv) all current directors and executive officers as a group. Except as otherwise indicated, we believe that the beneficial owners of the common stock listed below, based on information provided by such owners, have sole investment and voting power with respect to such shares, subject to community property laws where applicable. Persons, who have the power to vote or dispose of our common stock, either alone or jointly with others, are deemed to be beneficial owners of such common stock.\n\n \n\n**Title of Class**\n\n \n\n**Name and address of**\n\n**beneficial owner(1)**\n\n \n\n**Number of**\n\n**Shares Beneficially Owned**\n\n \n\n \n\n**Percent of class(2)**\n\n \n\n**Common Stock**\n\n \n\n**Named Executive Officers and Directors**\n\n \n\n \n\n \n\n \n\n \n\n \n\nCommon Stock\n\n \n\nPao-Chi Chu(3)*\n\n \n\n \n\n25,000,000\n\n \n\n \n\n \n\n12.08\n\n \n\nCommon Stock\n\n \n\nCheng-Hsiang Kao(4)*\n\n \n\n \n\n12,000,000\n\n \n\n \n\n \n\n5.80\n\n \n\nCommon Stock\n\n \n\nChe-Li Lin(5)*\n\n \n\n \n\n2,000,010\n\n \n\n \n\n \n\n0.97\n\n \n\nCommon Stock\n\n \n\nYen-Hsun Chen(6)*\n\n \n\n \n\n13,000,010\n\n \n\n \n\n \n\n6.28\n\n \n\nCommon Stock\n\n \n\nSsu-Chuan Lai(9)\n\n \n\n \n\n300,000\n\n \n\n \n\n \n\n0.15\n\n \n\nCommon Stock\n\n \n\nLi-Li Chu(7)\n\n \n\n \n\n39,999,980\n\n \n\n \n\n \n\n19.32\n\n \n\nCommon Stock\n\n \n\nLin-Lin Chu(8)\n\n \n\n \n\n17,000,000\n\n \n\n \n\n \n\n8.21\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nAll (former) directors, executive officers, and greater than 5% shareholders\n\n \n\n \n\n109,300,000\n\n \n\n \n\n \n\n52.81\n\n%\n\n \n\n * Former officer and/or director; resigned August 7, 2025.\n\n \n\n(1)\n\nUnless otherwise indicated, the business address of each of the individuals is c/o VitaSpring Biomedical Co., Ltd., 5225 Canyon Crest Drive, Suite 71-825, Riverside, CA 92507.\n\n \n\n \n\n(2)\n\nPercentage of beneficial ownership is based upon 207,030,030 shares of common stock.\n\n \n\n \n\n(3)\n\nPao-Chi Chu’s address is 2F, No. 356, Sec. 1, Dunhua S. Rd., Da’an Dist., Taipei City, 10600, Taiwan\n\n \n\n \n\n(4)\n\nCheng-Hsiang Kao’s address is 2F., No. 24, Aly. 6, Ln, 123, Sec. 5, Nanjing E. Rd., Songshan Dist, Taipei City, 10500, Taiwan\n\n \n\n \n\n(5)\n\nChe-Li Lin’s address is No. 210, 7th Neighborhood, Jilin Rd., Zhongshal Dist, Taipei City, 10469, Taiwan\n\n \n\n \n\n(6)\n\nYen-Hsun Chen’s address is 4F, No. 22, Ln. 119, Zhulin Rd., Yonghe Dist, New Taipei City, 234 Taiwan\n\n \n\n \n\n(7)\n\n8F-7, No. 81, Sec. 3, Bade Rd., Songshan Dist., Taipei City, 10500 Taiwan\n\n \n\n \n\n(8)\n\nNo 43-6, Shicaoikeng, Sanshi Dist., New Taipei City, 252, Taiwan\n\n \n\n \n\n(9)\n\nSsu-Chuan Lai is Director, President, Chief Executive Officer and Principal Financial Officer as of the filling of this report"}